Cell and Gene Therapy Bio-manufacturing Market Share, Size and Key Players Analysis 2026 to 2035
What is Cell and Gene Therapy Bio-Manufacturing Market Size?
Global Cell and Gene Therapy Bio-Manufacturing Market Size is valued at USD 15.22 Billion in 2025 and is predicted to reach USD 44.69 Billion by the year 2035 at an 11.5% CAGR during the forecast period for 2026 to 2035
Cell and Gene Therapy Bio-manufacturing Market Size, Share & Trends Analysis Report By Product Type (Consumables, Equipment, And Software Solutions), Usage (Commercial-Stage Manufacturing And Research-Stage Manufacturing), Application (Upstream Processing, Harvesting, And Downstream Processing), And End-User, By Region, And Segment Forecasts, 2026 to 2035
|
Get Free Sample Report
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Cell and Gene Therapy Bio-manufacturing Market Key Takeaways:
|
The global cell and gene therapy bio-manufacturing market is advancing. The cell and gene therapy industry is rapidly expanding due to its promise to cure chronic and rare/orphan diseases that previously had few therapeutic choices. The development of sophisticated medicines has been critical in redefining the treatment paradigm of various life-threatening and uncommon diseases, as well as in reshaping the biopharmaceutical sector. The rapid expansion of the advanced therapy landscape is a key driver of the cell and gene therapy manufacturing market.
However, due to its unprecedented scale and severity, the COVID-19 epidemic has significantly disrupted social, economic, and political activities all around the world. As a result, COVID-19 has upset the cell and gene therapy (CGT) sector, which has historically suffered from considerable complexity in the supply of materials, production, and logistical operations.
Competitive Landscape:
Some of the Cell and Gene Therapy Bio-manufacturing Market players are:
- Becton, Dickinson and Company
- Endress+Hauser Group Services AG (Analytik Jena GmbH)
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- General Electric Company (G.E. Healthcare)
- Getinge AB
- Infors AG
- Lonza Group Ltd
- Merck KGaA
- Miltenyi Biotec B.V. & Co. KG
- PIERRE GUERIN
- Sartorius AG (Sartorius Stedim Biotech S.A.)
- Thermo Fisher Scientific Inc.
- WuXi AppTec
Market Segmentation:
The cell and gene therapy bio-manufacturing market is segmented on the basis of product type, usage, application, and end-user. Based on product type, the market is categorized as consumables, equipment, and software solutions. The usage segment includes commercial-stage manufacturing and research-stage manufacturing. By application, the market is segmented into upstream processing, harvesting, and downstream processing. The end-user segment includes life science companies, contract research organizations (CROs), contract manufacturing organizations (CMOs), and cell banks.
The Commercial Stage Manufacturing Segment Led The Cell And Gene Therapy Bio-Manufacturing Market Based On Usage
The commercial stage manufacturing segment category is expected to hold a considerable share in the global cell and gene therapy bio-manufacturing Market in 2024. As the number of regulatory approvals for gene and cell therapy products grows, so does the demand for commercial production of these medicines. To meet shifting industry demands, key market players such as Thermo Fisher Scientific and AGC Biologics are launching a number of strategic initiatives. For example, Thermo Fisher Scientific will launch new Patheon Commercial Packaging Services for cell and gene therapy in the United States and Europe in February 2022. This comprehensive solution integrates logistics, serialization compliance, and global distribution. Such characteristics are predicted to provide a favorable environment for segment expansion.
Contract Manufacturing Organizations Witness Growth At A Rapid Rate
The contract manufacturing organizations segment is projected to grow at a rapid rate in the global cell and gene therapy bio-manufacturing market. With rising demand for cell and gene therapies, a need for manufacturing capacity is opening up new prospects for contract manufacturing service providers. Due to the non-standardized and frequently changing nature of the cell and gene therapy sector, outsourcing to a contract manufacturing service provider is likely to provide a competitive advantage in terms of experience and competence.
The North America Cell And Gene Therapy Bio-Manufacturing Market In The Region Holds A Significant Revenue Share
The North America Cell and Gene Therapy Bio-manufacturing Market is expected to register the highest market share in terms of revenue in the near future. This can be attributed to the region's rising involvement in gene and cell therapy research and product development, as well as a large number of contract development businesses. Also, domestic firms are increasing their production operations in the region.
Asia Pacific is expected to be a rising market for the production of cell and gene therapies. Cell treatment has gained traction in Asia during the last few years. This is due to the introduction of expedited approval procedures, increased healthcare requirements, and increased commercial and government spending.
Recent Developments:
- In January 2022, AllogeneTherapeutics Inc and AntionBiosciences Inc. formed an exclusive collaboration and global license agreement for Antion's miRNA technology (miCAR) to advance multiplex gene silencing as an additional tool in the development of next-generation allogeneic CAR T products.
Cell and Gene Therapy Bio-Manufacturing Market Report Scope:
| Report Attribute | Specifications |
| Market size value in 2025 | USD 15.22 Billion |
| Revenue forecast in 2035 | USD 44.69 Billion |
| Growth rate CAGR | CAGR of 11.5% from 2026 to 2035 |
| Quantitative units | Representation of revenue in US$ Billion, and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
| Segments covered | Product Type, Usage, Application, and End-User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; South Korea; Southeast Asia |
| Competitive Landscape | Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Danaher Corporation, Endress+Hauser Group Services AG (Analytik Jena GmbH), General Electric Company (G.E. Healthcare), Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. K.G., PIERRE GUERIN, Sartorius AG (Sartorius Stedim Biotech S.A.), Thermo Fisher Scientific Inc., and WuXi AppTec. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Cell and Gene Therapy Bio-manufacturing Market :
Cell and Gene Therapy Bio-manufacturing Market, By Product Type-
- Consumables
- Culture Supplements
- Media
- Serum
- Macronutrients
- Single-Use Liquids
- Cell Culture Reagents
- Cell Quantification Kits
- Culture Supplements
- Equipment
- Bioreactors/Fermenters
- Continuous Bioreactors
- Single-Use Bioreactors
- Mixing Systems
- Cell Counters
- Cell Sorters
- Centrifuges
- Incubators
- Biosafety Cabinets
- Freezers
- PCR Systems
- Transfection Systems
- Storage Tanks
- Others
- Bioreactors/Fermenters
- Software Solutions
Cell and Gene Therapy Bio-manufacturing Market, By Usage-
- Commercial Stage Manufacturing
- Research Stage Manufacturing
Cell and Gene Therapy Bio-manufacturing Market, By Application-
- Upstream Processing
- Formulation and Hydration
- Cell Culture Processing
- Harvesting
- Downstream Processing
- Separation and Filtration
- Fill and Finish Operations
Cell and Gene Therapy Bio-manufacturing Market, By End-User-
- Life Science Companies
- Equipment
- Consumables
- Software Solutions
- Contract Research Organizations (CROs)
- Equipment
- Consumables
- Software Solutions
- Contract Manufacturing Organizations (CMOs)
- Equipment
- Consumables
- Software Solutions
- Cell Banks
- Equipment
- Consumables
- Software Solutions
Cell and Gene Therapy Bio-manufacturing Market, By Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Cell and Gene Therapy Bio-Manufacturing Market Size is valued at USD 15.22 Billion in 2025 and is predicted to reach USD 44.69 Billion by the year 2035
Cell and Gene Therapy Bio-manufacturing Market expected to grow at a 11.5% CAGR during the forecast period for 2026 to 2035
Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Danaher Corporation, Endress+Hauser Group Services AG (Analytik Jena GmbH), General Electric Company (G.E. Healthcare), Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. K.G., PIERRE GUERIN, Sartorius AG (Sartorius Stedim Biotech S.A.), Thermo Fisher Scientific Inc., WuXi AppTec. and Others
Cell and gene therapy bio-manufacturing market is segmented on the basis of product type, usage, application, and end-user.
North America region is leading the Cell and gene therapy bio-manufacturing market.